Vanda receives positive CHMP opinion for HETLIOZ® (tasimelteon)
Vanda Pharmaceuticals announced that the EMA's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval of HETLIOZ® (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults in the European Union. April 24, 2015